Lee Yuchun 4
4 · VERTEX PHARMACEUTICALS INC / MA · Filed Jan 31, 2023
Insider Transaction Report
Form 4
Lee Yuchun
Director
Transactions
- Exercise/Conversion
Common Stock
2023-01-27$72.14/sh+1,429$103,088→ 3,304 total - Sale
Common Stock
2023-01-27$321.31/sh−379$121,776→ 2,925 total - Sale
Common Stock
2023-01-27$322.20/sh−970$312,534→ 1,955 total - Sale
Common Stock
2023-01-27$323.33/sh−80$25,866→ 1,875 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-01-27−1,429→ 0 totalExercise: $72.14Exp: 2024-05-31→ Common Stock (1,429 underlying)
Footnotes (5)
- [F1]Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1.
- [F2]Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- [F3]Open market sales reported on this line occurred at a weighted average price of $321.31 (range $320.62 to $321.59).
- [F4]Open market sales reported on this line occurred at a weighted average price of $322.20 (range $321.75 to $322.74).
- [F5]Fully vested.